About Us
Overview
The CTSR technology was invented by Simurx scientist, leveraging decades of experience in translational clinical research and application. Simurx’s multidisciplinary integrative approach to product development is keenly focused on implementing innovative solutions to cancer therapy. Simurx’s CTSR platform is a first of its kind technology that exploits the immunosuppressive nature of the tumor microenvironment to boost cell therapy efficiency and is protected by a broad patent filing.
We are motivated by a dedication to scientific rigor and the determination to improve cancer patient outcomes. Led by a skilled, innovative leadership team, supported by a multidisciplinary advisor team, and powered by committed scientists, Simurx is well positioned to bring a broad array of CAR treatments to cancer patients.
Leadership
Simurx is led by a highly experienced executive team with proven track records in translational and clinical cancer therapeutics.
![Shahab Asgharzadeh, MD Founder and Chief Executive Officer](https://simurx.com/wp-content/uploads/2024/07/Shahab-Asgharzadeh2-235x277.jpg)
Shahab Asgharzadeh, MD
![Babak Moghimi, MD Co-Founder and Chief Scientific Officer](https://simurx.com/wp-content/uploads/2024/07/Babak-Moghimi2-240x278.jpg)